查看文章

DISCUSSION: While incretin mimetic drugs are often used in the management of type two diabetes, their use is becoming increasingly common in the management of obesity given the beneficial weight loss profile. Tirzepatide, though not yet FDA-approved for the treatment of obesity, is a novel therapeutic agent that acts as a GLP-1 and GIP agonist. Given its GLP-1 agonism, Tirzepatide may decrease gastrointestinal motility resulting in intestinal obstruction (2). Of note, the patient had no history of abdominal or pelvic surgeries and had no history of inflammatory bowel disease to suggest other possible risk factors for bowel obstruction. Further research is required to explore this potentially life-threatening complication of Tirzepatide.

CONCLUSIONS: Tirzepatide is a novel therapeutic agent that acts as a GLP-1 and GIP agonist. Clinicians should be aware that Tirzepatide, and other similar drugs, may cause rare yet …